Philip M. Hanno, MD, MPH
Philip M. Hanno, a Urology Times editorial consultant, is professor of urology at the University of Pennsylvania, Philadelphia.
http://www.urologytimes.com
Urology, gynecology collaboration addresses rising demand
In this interview, Sarah E. McAchran, MD, discusses the need for urology-gynecology collaboration, the background behind the ABMS recognizing the female pelvic medicine and reconstructive surgery subspecialty, and how barriers to full integration of providers treating pelvic floor disorders can be overcome.
Chronic scrotal pain: How you can assist patients
In this interview, Daniel Shoskes, MD, discusses his evaluation of patients with scrotal pain, outlines his use of conservative treatments, and explains surgical approaches and how he decides whether to use them.
Wellness in urology: Consider non-drug measures up front
In this interview, Mark A. Moyad, MD, MPH, discusses non-drug interventions for urologic conditions, the difference between prescription drugs and nutraceuticals, and why a heart-healthy diet is a prostate-healthy diet.
Physician work force advocate Dr. Cooper remembered
Richard “Buz” Cooper, MD, an outspoken figure on health care work force shortages, dies at 79.
CNS may be path to future voiding dysfunction therapies
In this interview, Karl-Erik Andersson, MD, PhD, discusses current treatments for common voiding dysfunctions and future directions, including central nervous system agents and combination therapies.
IC/BPS: Agent brings glimmer of hope
IC/BPS: Agent brings glimmer of hope
For the desperate patient with severe symptoms and a contracted, inflamed bladder who has failed standard therapies, cyclosporine A can be an effective treatment and prevent or delay the need for cystectomy and/or urinary diversion.
Violence against urologists: Data, communication needed
In this interview, Eugene Y. Rhee, MD, MBA, discusses violent acts committed against urologists, the challenges of collecting and sharing data on potentially dangerous patients, and what some institutions are doing to protect their practices.
Decision to use testosterone must be individualized
Testosterone replacement therapy has been much debated in recent months, in light of two studies linking the treatment to increased risk of all-cause mortality, myocardial infarction, and stroke, prompting an FDA investigation into TRT’s safety and widespread criticism from members of the urologic community. In this article, Ajay Nehra, MD, discusses those studies, evolving attitudes toward “low T,” and the importance of individualizing treatment.
Urologist, former regulator shares FDA insights
Urologist Daniel Shames, MD, has had a unique and varied career, with stops in clinical practice, the FDA, and his current role as a consultant to the pharmaceutical industry. Dr. Shames’ wide-ranging experience brings an insightful perspective on the topics he discusses in this interview: what goes into FDA drug approvals, quality of life endpoints, and the Sunshine Act.

Poll